Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

13.0%

12 terminated/withdrawn out of 92 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

16%

15 trials in Phase 3/4

Results Transparency

56%

27 of 48 completed trials have results

Key Signals

21 recruiting27 with results10 terminated

Enrollment Performance

Analytics

Phase 1

35(46.7%)

Phase 2

23(30.7%)

Phase 3

15(20.0%)

Early Phase 1

1(1.3%)

N/A

1(1.3%)

75Total

Phase 1(35)

Phase 2(23)

Phase 3(15)

Early Phase 1(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (92)

Showing 20 of 92 trials

NCT07575308Phase 2Not Yet Recruiting

HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

Role: lead

NCT05231785Phase 1Recruiting

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

Role: lead

NCT06659640Phase 1Recruiting

A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Role: lead

NCT06600321Phase 1Recruiting

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Role: lead

NCT06585449Phase 1Recruiting

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

Role: lead

NCT06423352Phase 1Completed

A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension

Role: lead

NCT07553442Phase 2Not Yet Recruiting

A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

Role: lead

NCT04883905Recruiting

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

Role: lead

NCT07358078Recruiting

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

Role: lead

NCT06393712Phase 2Recruiting

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

Role: lead

NCT04982393Active Not Recruiting

BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

Role: lead

NCT07214727Phase 1Recruiting

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Role: lead

NCT05040373Recruiting

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

Role: lead

NCT03997383Phase 3Completed

APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Role: lead

NCT07223203Phase 3Recruiting

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

Role: lead

NCT07295717Phase 1Recruiting

A Study to Evaluate ALN-4285 in Adult Healthy Volunteers

Role: lead

NCT07181109Phase 3Recruiting

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Role: lead

NCT06845202Phase 1Recruiting

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

Role: lead

NCT07465224Phase 2Recruiting

A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

Role: lead

NCT07052903Phase 3Recruiting

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Role: lead